STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13G/A] Arcus Biosciences, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Arcus Biosciences (RCUS): Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen filed an amended Schedule 13G reporting beneficial ownership of 4,332,479 Arcus common shares, equal to 4.1% of the class as of September 30, 2025.

The reporting persons have 0 shares with sole voting or dispositive power and 4,332,479 shares with shared voting and shared dispositive power. They certified the holdings were not acquired with the purpose or effect of changing or influencing control.

Positive
  • None.
Negative
  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Point72 Asset Management, L.P.
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:11/14/2025
Point72 Capital Advisors, Inc.
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:11/14/2025
Steven A. Cohen
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:11/14/2025

FAQ

What stake in RCUS did Point72 and Steven A. Cohen report?

They reported beneficial ownership of 4,332,479 shares, representing 4.1% of Arcus Biosciences’ common stock as of September 30, 2025.

Which entities are the reporting persons in this RCUS 13G/A?

The filing lists Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen.

How is voting and dispositive power allocated for the RCUS shares?

The reporting persons have 0 shares with sole voting/dispositive power and 4,332,479 shares with shared voting and shared dispositive power.

What type of filing was submitted for RCUS?

An amended Schedule 13G (13G/A), which reports passive beneficial ownership of a public company’s equity securities.

What did the certification state regarding control of Arcus Biosciences?

They certified the securities were not acquired and are not held for the purpose or effect of changing or influencing control.

What is the as-of date for the ownership figures?

The ownership information is stated as of September 30, 2025.
Arcus Bioscience

NYSE:RCUS

RCUS Rankings

RCUS Latest News

RCUS Latest SEC Filings

RCUS Stock Data

2.45B
85.76M
34.73%
67.52%
9.24%
Biotechnology
Pharmaceutical Preparations
Link
United States
HAYWARD